Plain-English translation of NCT05039632 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new treatment approach for people with advanced cancer that has spread to the lungs or liver. The study combines three components: an injection of a medication called NBTXR3 placed directly into a tumor, radiation therapy, and immunotherapy (a type of drug that helps your immune system fight cancer). Researchers want to see if this combination is safe and effective.
Standard treatments for advanced cancer that has spread don't work well for everyone. This trial is exploring whether adding a targeted injectable medication to radiation and immunotherapy might help more patients by making the immune system better able to recognize and attack cancer cells throughout the body.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive an injection of the medication directly into one of your tumors on day 1, followed by immunotherapy by IV infusion on day 8. Starting on day 15, you will receive radiation therapy over 1–2 weeks. After that, you will continue immunotherapy infusions every 3–6 weeks for up to 2 years, as long as your cancer is not progressing and you are tolerating the treatment well. You will have regular follow-up visits to check how you are responding and to monitor for any side effects.
AI-generated summary from trial data · Aug 15, 2026 · Not medical advice
United States